Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI

NCT ID: NCT03021577

Last Updated: 2025-08-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-25
• Study Completion Date: 2019-03-16

Brief Summary

The investigators hypothesize that the orbital atherectomy system (OAS), a newer generation atherectomy device, reduces the incidence of microcirculatory compromise as compared to older generation rotational atherectomy (RA) due to differences in the mechanism of athero-ablation.

Detailed Description

The presence of heavily calcified coronary lesions necessitates the use of ablative devices that aid in successful percutaneous coronary intervention (PCI). However, atherectomy devices generate microparticles that embolize to the distal coronary microcirculation and may compromise myocardial tissue perfusion.

Two mechanisms that deserve particular attention are the eccentric mounting of the OAS crown and the higher flow rates on the vasodilator flush. Firstly, as opposed to rotational atherectomy where the larger, centrally mounted burr may cause obstruction of flow during the atherectomy, the smaller eccentrically mounted crown in OAS allows continuous perfusion during both atherectomy as well as rest periods. Second, both during rest and atherectomy, the flow rates of vasodilatory flush is higher in OAS compared to RA. Combined, these differences in coronary and vasodilator flush flow could lead to improved perfusion of the distal circulation, particularly during the atherectomy runs when risk of embolization is highest.

The loss of microcirculatory function can be transient, with partial or complete restoration of microcirculatory blood flow, or permanent. As shown in studies of patients with acute coronary syndromes, the loss of microcirculatory function is a critical and independent predictor of myocardial recovery and adverse outcomes. The putative protective effects of OAS on coronary microvasculature may therefore be of major clinical significance and impact.

Conditions

Coronary Artery Disease (CAD)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Orbital Atherectomy System (OAS) Group

Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Group Type: ACTIVE_COMPARATOR

Orbital Atherectomy System (OAS)

Intervention Type: DEVICE

The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.

Magnetic Resonance Imaging (MRI)

Intervention Type: PROCEDURE

In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Rotational Atherectomy (RA) Group

Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Group Type: ACTIVE_COMPARATOR

Rotablator Rotational Atherectomy System

Intervention Type: DEVICE

The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console

Magnetic Resonance Imaging (MRI)

Intervention Type: PROCEDURE

In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Interventions

Orbital Atherectomy System (OAS)

The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.

Intervention Type: DEVICE

Rotablator Rotational Atherectomy System

The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console

Intervention Type: DEVICE

Magnetic Resonance Imaging (MRI)

In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years

2. Patient with an indication for PCI including:

• Angina (stable or unstable),
• Silent ischemia (a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present),
• Non-ST Segment Elevation Myocardial Infarction (NSTEMI)

3. Patients will undergo cardiac catheterization and possible or definite PCI with intent to stent using any non-investigational metallic drug-eluting stent (DES)

4. Signed written informed consent

5. Heavily calcified (severe)lesions necessitating atherectomy.

1. The target lesion must be located in a native coronary artery with visually estimated reference vessel diameter of ≥2.25 mm to ≤4.00 mm.

2. Lesion length between 20 mm and 50mm

Exclusion Criteria

1. Estimated creatinine clearance <30 ml/min using Cockcroft-Gault equation, unless the patient is on dialysis;

2. ST-elevation Myocardial Infarction (STEMI) within 24 hours of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital.

3. PCI within 24 hours preceding the study procedure.

4. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure <90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including intra-aortic balloon pump (IABP), at time of procedure.

5. Mobitz II second degree or complete heart block

6. Malignant ventricular arrhythmias requiring treatment

7. Pulmonary edema defined as patient with shortness of breath, evidence of volume overload on physical exam, and crepitations on physical exam (>1/3 of lungs) or radiographic interstitial or alveolar pulmonary edema

8. Subject is intubated.

9. Known left ventricular ejection fraction (LVEF) <35%.

10. Severe valvular disease (e.g. severe mitral regurgitation or severe aortic stenosis)

11. Patient is participating in any other investigational drug or device clinical trial that has not reached its primary endpoint.

12. Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test within one week before treatment).

General Inclusion - MRI Sub-Study

1. Patients with no prior MI/scarring in the subtended myocardial territory.

2. Patients with no contraindication for MRI studies

3. Patients who could safely receive Gadolinium (i.e. estimated glomerular filtration rate (eGFR) >30)

1. Lesion length <20mm

2. Study target lesion in a bypass graft

3. Ostial right coronary artery (RCA) study target lesion

4. Chronic total occlusion (Thrombolysis In Myocardial Infarction (TIMI) flow 0/1) study target lesion

5. Bifurcation study lesion with a planned dual stent strategy

6. In-stent restenosis study target lesion

General Inclusion - MRI Sub-Study

1. Patients with no prior myocardial infarction (MI)/scarring in the subtended myocardial territory.

2. Patients with no contraindication for Magnetic resonance imaging (MRI) studies

3. Patients who could safely receive Gadolinium (i.e. eGFR>30)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Jeffrey W. Moses

Professor of Cardiology in Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ziad A. Ali, MD

Role: STUDY_CHAIR

Columbia University

Jeffrey W. Moses, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Columbia University

New York, New York, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

AAAQ9267

Identifier Type: -

Identifier Source: org_study_id